What is CF?
Real Facts for You
Did you know that over 1000 mutations in the CFTR gene can lead to cystic fibrosis?Learn More
Join a Study
Finding Solutions Together
Participate in a research study of new cystic fibrosis therapies at Johns Hopkins.Learn More
Follow Us on Twitter @HopkinsCF
Find Us on Facebook
Eradication Guidelines for Pseudomonas aeruginosa Eradication Published
January 23, 2015
Cystic Fibrosis Foundation Pulmonary Clinical Practice Guidelines Committee chaired by Dr. Mogayzel has published the guidelines for the eradication for Pseudomonas aeruginosa in the Annals of the American Thoracic Society.
Two Research Studies on Sleep and CF Are Now Enrolling.
January 10, 2015
Studies of “Sleep-Related Ventilatory Mechanics & Energy Expenditure in Children and Adults with Cystic Fibrosis” and “Use of High Flow Nasal Insufflation in Children and Adults with Cystic Fibrosis” are now enrolling. Get more information
FDA Expands the Indication for Ivacaftor
December 30, 2014
The Food & Drug Administration has approved an expansion of the indication for ivacaftor (Kalydaco) to include people with CF due to at least one R117H CFTR mutation. Ivacaftor is now approved for use in the U.S. in people ages 6 and older with CF with one of the following ten CFTR mutations: R117H, G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P or G1349D.
New Issue of Partners in Discovery Available
December 30, 2014
The Winter 2015 issue of Partners in Discovery is now available. Read it now.
Learn More About CF Research at Johns Hopkins
December 28, 2014
Hopkins CF Newsletter: Partners in Discovery
Issue: Winter 2015
The Transition: As the average life expectancy of patients with CF has risen dramatically over the past 20 years, more and more patients are living on their own, attending college and pursuing careers. DOWNLOAD PDF | SIGN-UP
Family Day Presentations Are Available Online
The recorded webcast of our Annual Johns Hopkins CF Center Family Education Day is now available. Dr. Michael Boyle was our keynote speaker. His presentation was entitled The Journey to Delivering Transformational CF Therapeutics.